Abstract: This study investigated the diagnostic value of ultrasound (US) combined with serum osteopontin (OPN) and interleukin-1β (IL-1β) in breast cancer bone metastasis. 60 breast cancer patients were examined by US, and the serum OPN and IL-1β levels were measured by enzyme-linked immunosorbent assay (ELISA). The results showed that the sensitivity of US in diagnosing bone metastases was 82.35% and the specificity was 80.77%. Compared with patients without bone metastases, the serum OPN and IL-1β levels in patients with bone metastases were significantly higher (P<0.001). Compared with patients in the US negative group, the levels of serum OPN and IL-1β in the US positive group were significantly increased (P<0.001). The serum OPN and IL-1β levels gradually increased with the increase of US grade (P<0.05). The sensitivity and specificity of OPN were 52.94% and 96.15% in the diagnosis of bone metastases, respectively. The sensitivity of IL-1β in diagnosing bone metastasis was 82.35% and the specificity was 84.62%. The sensitivity of OPN combined with IL-1β in the diagnosis of bone metastasis was 79.41%, and the specificity was 80.77%. US, OPN and IL-1β all play different roles in the diagnosis of breast cancer bone metastases, among which US and IL-1β have a higher sensitivity and OPN has a higher specificity, and the combination is more conducive to the early diagnosis of breast cancer bone metastases.

Key words: ultrasound, breast cancer, bone metastasis, osteopontin, interleukin-1β